x

Posted 12 October, 2021

Bellerophon Therapeutics, Inc. appointed new CEO

CEO Change detected for ticker Nasdaq:BLPH in a 8-K filed on 12 October, 2021.


  Resignation of Chief Executive Officer  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Bellerophon Therapeutics, Inc.
Health Care/Life Sciences • Pharmaceuticals
Bellerophon Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. Its product pipeline includes PH-ILD, PH-COPD, INOpulse and PH-Sarc. The company was founded in 2009 and is headquartered in Warren, NJ.
Market Cap
$630K
View Company Details
Bellerophon Therapeutics, Inc. by TradingView
Relevant filing section
Item 5.02. Departure of Directors or Certain Officers; Election of Directs; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Resignation of Chief Executive Officer


On October 7, 2021, Fabian Tenenbaum, the Chief Executive Officer of Bellerophon Therapeutics, Inc. (the "Company"), notified the Company's Board of Directors that he will resign as Chief Executive Officer and as a director of the Company and its subsidiaries, effective October 24, 2021, to pursue other opportunities. Mr. Tenenbaum's decision to resign is not due to any disagreement with the Company on any matters relating to the Company's operations, policies, or practices. The Company plans to engage in a search to identify a successor to Mr. Tenenbaum.






2